{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:35:23Z","timestamp":1740144923604,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/09180-0"],"award-info":[{"award-number":["2016\/09180-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary cutaneous CD30+ lymphoproliferative disorders (pc-CD30-LPD) are a group of clonal T cell lymphoproliferative disorders that despite very similar tumor histology follow different and characteristic clinical courses, suggesting a homeostatic role of the tumor microenvironment. Little is known about tumor microenvironment and there is almost no literature about PD-L1 expression in pc-CD30-LPD.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study presents a fully clinicopathologically characterized series of pc-CD30-LPDs from an academic medical center in Brazil, including 8 lymphomatoid papulomatosis (LyP), 9 primary cutaneous anaplastic large cell lymphoma (pcALCL) and 4 borderline lesions. All the cases were scored for FOXP3+ regulatory T-cells (Treg) and CD8+ cytotoxic tumor infiltrating lymphocytes (TIL) densities, as well as PD-L1 expression in tumor cells and tissue associated macrophages. The CD8+\/FOXP3+ ratio was also evaluated.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 21 cases of pc-CD30-LPD, PD-L1 expression is frequent in both tumor cells and tissue associated macrophages in pc-CD30-LPD across categories, suggesting that the PD-L1 axis may be a common feature of pc-CD30-LPDs. While reactive T cell infiltrates vary widely from case to case, a common feature across pc-CD30-LPDs is higher density of CD8 than FOXP3\u2009+\u2009T cells. The distribution of T cells within the lesions however differed between LyP and pcALCL: we found that LyP lesions tend to be permeated by CD8+ and FOXP3+ T cells, whereas pcALCL tend to be surrounded by a rim of CD8+ TIL and FOXP3+ Tregs with relatively lower density infiltrates in the center of the lesion.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>LyP has a trend to have denser immune cells throughout the lesion, with higher FOXP3+ Treg and CD8+ TIL in the center than the edge comparing with pcALCL. PD-L1+ is frequent in tumor cells and tissue associated macrophages in pc-CD30-LPD. The differential distribution of CD8+ and FOXP3+ TILs in LyP as compared to pcALCL could provide a clue to the relapsing\/remitting course of LyP as compared to the less frequent spontaneous regression of pcALCL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-019-0900-7","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T04:28:23Z","timestamp":1571804903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26\u2009year experience from an academic medical center in Brazil"],"prefix":"10.1186","volume":"14","author":[{"given":"Cristiane R\u00fabia","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Miyashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Cury-Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymundo Soares","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C. N.","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dita","family":"Gratzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"900_CR1","first-page":"392","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (Revised 4th edition)","author":"R Willemze","year":"2017","unstructured":"Willemze R, Paulli M, Kadin ME. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, et al., editors. (Eds) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (Revised 4th edition). Lyon: IARC; 2017. p. 392\u20136."},{"key":"900_CR2","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphoma. Blood. 2005;105:3768\u201385.","journal-title":"Blood"},{"key":"900_CR3","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653.012k23_3653_3661","volume":"95","author":"MW Bekkenk","year":"2000","unstructured":"Bekkenk MW, Geelen FA, van Voorst Vander PC, et al. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653\u201361.","journal-title":"Blood"},{"key":"900_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.semdp.2016.11.005","volume":"34","author":"W Kempf","year":"2017","unstructured":"Kempf W. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol. 2017;34:22\u201335.","journal-title":"Semin Diagn Pathol"},{"key":"900_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","volume":"25","author":"GA Rabinovich","year":"2007","unstructured":"Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267\u201396.","journal-title":"Annu Rev Immunol"},{"key":"900_CR6","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","volume":"114","author":"RA Wilcox","year":"2009","unstructured":"Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppress host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114:2149\u201358.","journal-title":"Blood"},{"key":"900_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265\u201376.","journal-title":"Trends Immunol"},{"key":"900_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109\u201318.","journal-title":"Cell Res"},{"key":"900_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1600-065X.2008.00649.x","volume":"224","author":"KS Peggs","year":"2008","unstructured":"Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer. Immunol Rev. 2008;224:141\u201365.","journal-title":"Immunol Rev"},{"key":"900_CR10","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Franciso","year":"2009","unstructured":"Franciso LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015\u201329.","journal-title":"J Exp Med"},{"key":"900_CR11","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.molonc.2015.10.008","volume":"9","author":"A Sledzinska","year":"2015","unstructured":"Sledzinska A, Menger L, Bergerhoff K, et al. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol. 2015;9:1936\u201365.","journal-title":"Mol Oncol"},{"key":"900_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330\u20136.","journal-title":"Nat Immunol"},{"key":"900_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/cup.12719","volume":"43","author":"A De Souza","year":"2016","unstructured":"De Souza A, Tinguely M, Burghart DR, et al. Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophage. J Cutan Pathol. 2016;43:579\u201388.","journal-title":"J Cutan Pathol"},{"key":"900_CR14","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/sj.leu.2404913","volume":"21","author":"LM Gjerdrum","year":"2007","unstructured":"Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia. 2007;21:2512\u20138.","journal-title":"Leukemia"},{"key":"900_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1600-0609.2008.01064.x","volume":"80","author":"LM Gjerdrum","year":"2008","unstructured":"Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations. Eur J Haematol. 2008;80:483\u20139.","journal-title":"Eur J Haematol"},{"key":"900_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"YH Kim","year":"2007","unstructured":"Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:479\u201384.","journal-title":"Blood"},{"key":"900_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2217\/imt-2015-0029","volume":"8","author":"R Gentzler","year":"2016","unstructured":"Gentzler R, Hall R, Kunk PR, et al. Beyond melanoma: inhibiting the PD-1\/PD-L1 pathway in solid tumors. Immunotherapy. 2016;8:583\u2013600.","journal-title":"Immunotherapy"},{"key":"900_CR18","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179.","journal-title":"Sci Rep"},{"key":"900_CR19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7150\/jca.14549","volume":"7","author":"Z Li","year":"2016","unstructured":"Li Z, Dong P, Ren M, et al. PD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patient. J Cancer. 2016;7:784\u201393.","journal-title":"J Cancer"},{"key":"900_CR20","doi-asserted-by":"crossref","first-page":"71455","DOI":"10.18632\/oncotarget.12213","volume":"7","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Li M, Mu D, Kong L, et al. CD8+\/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget. 2016;7:71455\u201365.","journal-title":"Oncotarget"},{"key":"900_CR21","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.7150\/jca.18683","volume":"8","author":"Y Que","year":"2017","unstructured":"Que Y, Xiao W, Guan YX, Liang Y, et al. PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer. 2017;8:2018\u201325.","journal-title":"J Cancer"},{"key":"900_CR22","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","volume":"108","author":"J Carreras","year":"2006","unstructured":"Carreras J, Lopes-Guillermo A, Fox BC, et al. FOXP3-positive regulatory T-cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957\u201364.","journal-title":"Blood"},{"key":"900_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.11702","volume":"93","author":"A Tzankov","year":"2008","unstructured":"Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin\u2019s lymphoma. Haematologica. 2008;93:193\u2013200.","journal-title":"Haematologica"},{"key":"900_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1756-8722-4-50","volume":"4","author":"J Wang","year":"2011","unstructured":"Wang J, Ke XY. The four types of Tregs in malignant lymphomas. J Hematol Oncol. 2011;4:50.","journal-title":"J Hematol Oncol"},{"key":"900_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurach M. Molecular and cellular insights into T cell exhaustion. Nature Rev Immunol. 2015;15:486\u201399.","journal-title":"Nature Rev Immunol"},{"key":"900_CR26","first-page":"492","volume":"30","author":"Y Gong","year":"2017","unstructured":"Gong Y, Chen R, Zhang X, et al. Role of immune microenvironmental factors for improving the IPI-related risk stratification of aggressive B cell lymphoma. Biomed Environ Sci. 2017;30:492\u2013500.","journal-title":"Biomed Environ Sci"},{"key":"900_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.coi.2015.02.003","volume":"33","author":"R Roychoudhuri","year":"2015","unstructured":"Roychoudhuri R, Eil RL, Restifo NP, et al. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol. 2015;33:101\u201311.","journal-title":"Curr Opin Immunol"},{"key":"900_CR28","doi-asserted-by":"publisher","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-06-1822","volume":"66","author":"ZZ Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Ziesmer SC, et al. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2006;66:10145\u201352.","journal-title":"Cancer Res"},{"key":"900_CR29","first-page":"572","volume":"141","author":"K Sideras","year":"2017","unstructured":"Sideras K, Biermann K, Yap K, et al. Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. In J Cancer. 2017;141:572\u201382.","journal-title":"In J Cancer"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0900-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-019-0900-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0900-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:20:29Z","timestamp":1603236029000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-019-0900-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1186\/s13000-019-0900-7","relation":{},"ISSN":["1746-1596"],"issn-type":[{"type":"electronic","value":"1746-1596"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"11 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was approved by the Research Project Review Ethics Committee of The Clinics Hospital of Sao Paulo University Medical School (CAPPesq n\u00b0 15486). Due to the retrospective model of this study no specific informed consent was needed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}